Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
To be fair kaeren if it hadn't have been sensitive to the B variants it would have been a huge waste of time and money going to the effort of a CE mark and cdta. The next dominant variant is already out there and will be an omicron descendant, Centaurus ba.275 being the likely culprit by autumn, but you never know. Be interesting to see whether the UK government holds back it's autumn booster campaign until a reformulated omicron specific vax is released.
Gazman, I guess it could be held as an egm resolution closer to his being in the position for 12months which it would have been had the AGM not been moved forward from late September. He could throw his toys out of the pram and bail if he's not happy with the situation, his choice, based on what I've seen so far I couldn't care less. H1 is entirely his to own, he can't blame the previous CEO for that.
No need for apologies, both are invisible from the shareholder's point of view. Wouldn't surprise me if they put Mandy front and center next week.
Wakefield is the Homer disappearing GIF personified.
1010 recorded cases mostly in under 5s, 46 liver transplants (5%), 22 deaths (2%). The consensus seems to be adenovirus although that's far from settled, it's why NCYT are knocking up the adenovirus assay though.
The 1010 will be a significant undercount, particularly in developing nations.
https://t.co/H2nPUfpfix
Imo this is because there's no capacity to test outside of a very narrow subset of the population and the limitations of currently carrying out all testing at PD. The US seems to have realized that they're massively underestimating cases and began to expand testing outside of CDC labs only We'll realize when it's made it's move into the wider population, a day late and a dollar short.
https://t.co/HJmro3NMoH
Ba.2 was dominant and ba.4 & 5 were both sequencing in significant numbers when it was launched, no reason to think it wouldn't. Earlier developed RATs aren't having a problem detecting these variants.
Piscean, refer to the ltip rns 4 Feb. On the face of it no they would not benefit as anything below £3.54 would mean they've failed to achieve the minimum target. There is no other bonus structure in place, nor do any of them have millions of cheap shares salted away.
All things being equal there's no incentive to sell us out cheap, just ineptitude or a desire to bring in an institution at a preferential price at our expense. The board would struggle to justify a dilutive placing to shareholders with our cash balance. Imo
Wilson further to the lft reader, promate 2g (ambient) has also been given a CE mark allowing it to be shipped and stored anywhere at room temperature and it wasn't even worth more than a brief mention in this rns?
We're having the p@ss roundly taken out of us, they've had plenty to tell us. Just couldn't be bothered. I know their comms have been bad but significant product launches wrapped up in this sack of crap? Incandescent doesn't even come close.
Little wonder they've opted for a virtual AGM.
Wilson it's pathetic, many LFT positives are barely discernable to the human eye yet you'd still be contagious due to the low sensitivity of LFTs. So I can see demand in a number of settings where PCR isn't cost effective/practical but accuracy is critical.
Tedros (WHO) has said only this morning that monkey pox is presenting a significant challenge largely due to a lack of testing capacity, availability. If we cannot make inroads there then we may as well shut up shop. 58 countries thus far.
They released the H1 trading update on 17th July 2020 and they'll have broke their necks to get that out considering the revenue growth. It was deliberate no doubt today, why? No idea.
If we 100% lose the dispute (or fractions of it), we'll be able to reclaim any Corp tax and vat paid on it which is significant. We won't be left penny less. It's certainly not an outcome that I'd relish though.
@kaeren, perhaps they know they don't have the votes to carry Allmonds ratification. They know they cannot reasonably dilute shareholders by way of a placing and a board friendly II with our cash balance. Drop a sh@t update as soon as possible after H2, cause a panic and then get someone in cheap to get him across the line. Likely far fetched but disgraceful if it's anywhere near true.
As pointed out earlier in the week, they just lost around 10% of votes cast when Bio reduced.
We'll end up repay nothing imo, the company won't have held out this long if we're demonstrably at fault. However, we now need to see progress towards a resolution not more of 'we'll tell you what the f@ck we like, ie nothing'. It's long past the point where 'we have a strong contractual position' was sufficient to fulfil your fiduciary to the only people you answer to, shareholders. To be frank it's beginning to stink of this NDA being convenient for both parties.
Shareholders need to put Allmond on notice by voting down his ratification, his ratification can be delayed until he delivers quantifiable progress. He may find that unpalatable and if he does then he should consider polishing up his linkdin profile, CEOs of the calibre he's shown thus far are ten a penny.
He hid away for six months to deliver what exactly? There is undoubtedly some interesting developments in that update but questions need answering surrounding other developments, namely.
Why was coprep 6 months late when it was penciled in for immediate release and then released as a tweet, the first developement since the acquisition of it/is?
Why did it take twelve effing months to get a CE mark on the antigen self test when it was allegedly ready to go in June 2021?
Who OK'd the purchase of £30m of inventory, subsequently written off. Considering it no longer forms part of the counterclaim there's no reason to avoid discussing it by hiding behind the NDA. The then CEO, current CFO and current Chairman must of signed it off without a cast iron guarantee that it would be taken on by the DHSC or NCYT having a fallback strategy for its sale, resulting in the p@ssing away of 40p per share at cost. Conveniently swept under the carpet by the current Board.
We don't want to hear talk of M&A opportunities, get off your asses and do it.
Stop it with the we have a deal with a major 'not to be named' global company/NGO crap.
Take the disgraceful remuneration resolution off of the table, it's an insult to your shareholders. Do you want to face the embarrassment of having it voted down?
While you're at it pull the share buy back resolution, it's a sham. You're trading well below cash yet haven't seen fit to action the resolution that you already had in place.
Our invisible Chairman needs to put his hands in his pockets or frankly do one.
Finally, grow a set and have an IRL AGM you utterly gutless bluffers.
I've voted against his ratification and the remuneration resolutions, it may be pyrrhic but they're my votes to cast.
If ever people needed a kick up the arse to vote, that's it. F*** any thought of a remuneration increase or frankly ratifying his appointment. PIs need to get this across to him.
There's actually some good stuff in there with regard to non covid r&d and near term releases but all wrapped up in a **** sandwich.
No wonder the coward doesn't dare face shareholders.
The dispute needs settling, cash burn is not a worry assuming a decent out come.
He's done, the rank and file will take over the 1922 next week, get rid of the 1 yr moratorium and have another vote of no confidence before the recess. They already have the letters, he won't survive another vote. It's up to him if he wants to face the embarrassment of being dumped by his own members.